Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{185228,
        author = {Chhavi Rana and Dr. Lekha Singh and Kasak Chaudhary and Navin Parmar and Shani Parjapati and Sahdev and Akhilesh Gupta and Ajit Kumar},
        title = {Hepatitis B: Viral genome, HBV and HIV co-infection, Antiviral Therapy and Diagnosis},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {5},
        pages = {424-438},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=185228},
        abstract = {Infection with hepatitis B is a major worldwide health concern. Frequently spread through bodily fluids such as blood, semen, and vaginal secretions and lead to wide range of liver disease including acute to chronic hepatitis, fulminant hepatitis, cirrhosis and hepatocellular carcinoma. Hepatitis B infection infects more than 262 million people worldwide that leading to around 820,000 deaths annually. In order to accomplish the objective of eradicating viral hepatitis (particularly chronic B and C), and sexually transmitted disease by 2030, the health sector is guided by global health sector strategies on viral hepatitis but currently no countries are on track to achieve this goal. All patient with hepatitis B surface antigen (HbsAg) should receive treatment until HBsAg is undetectable for 12 months. We are going to review on epidemiology, HBV and HIV coinfection, mode of transmission, antiviral therapy, as well as their Diagnostic evaluation and its future approaches},
        keywords = {HBV, epidemiology, viral genome, HBV / HIV coinfection, Antiviral therapy, diagnostic evaluation},
        month = {October},
        }